** Shares of drug developer Adaptimmune Therapeutics
rise ~3% to 81 cents
** Co says its cell therapy being developed to treat two rare types of cancers met the main goal of a mid-stage study
** The therapy, lete-cel, helped 42% of study patients achieve partial or complete response to the treatment - ADAP
** Co plans to begin application process for lete-cel in 2025 for the treatment of both synovial sarcoma and myxoid/round cell liposarcoma (MRCLS) - ADAP
** Synovial sarcoma is a cancer in the soft tissues that most often affects young people and MRCLS is a cancer that grows in the cells that store fat in the body
** Including session gains, stock up ~2% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。